44 related articles for article (PubMed ID: 27260644)
1. Impact of Everolimus Initiation and Corticosteroid Weaning During Acute Phase After Heart Transplantation on Clinical Outcome: Data from the Korean Organ Transplant Registry (KOTRY).
Lee KS; Kim H; Lee SH; Choi DJ; Yoon M; Jeon ES; Choi JO; Kang J; Lee HY; Jung SH; Oh J; Kang SM; Lee SY; Ju MH; Kim JJ; Kim MS; Cho HJ
Transpl Int; 2024; 37():11878. PubMed ID: 38644935
[TBL] [Abstract][Full Text] [Related]
2. mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy.
Kreienbaum H; Stiller B; Kubicki R; Bobrowski A; Kroll J; Fleck T
Pediatr Transplant; 2024 Mar; 28(2):e14698. PubMed ID: 38433342
[TBL] [Abstract][Full Text] [Related]
3. Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V; Abdelhamid K; Noto A; Latifyan S; Martina F; Daoudlarian D; De Micheli R; Pruijm M; Peters S; Hullin R; Gaide O; Pantaleo G; Obeid M
Nat Commun; 2024 Apr; 15(1):3664. PubMed ID: 38693123
[TBL] [Abstract][Full Text] [Related]
4. Different Patterns of Foxp3 Gene Expression in Pre-and Post-Transplantation Kidney Biopsies and the Effect of Use Mammalian Target of Rapamycin Inhibitors.
Caldas HC; Gonçalves NDN; Costa DS; Dias C; Caires LP; Baptista MASF; Fernandes-Charpiot IMM; Abbud-Filho M
Transplant Proc; 2023; 55(6):1408-1410. PubMed ID: 37156660
[TBL] [Abstract][Full Text] [Related]
5. First-in-human therapy with Treg produced from thymic tissue (thyTreg) in a heart transplant infant.
Bernaldo-de-Quirós E; Camino M; Martínez-Bonet M; Gil-Jaurena JM; Gil N; Hernández-Flórez D; Fernández-Santos ME; Butragueño L; Dijke IE; Levings MK; West LJ; Pion M; Correa-Rocha R
J Exp Med; 2023 Dec; 220(12):. PubMed ID: 37906166
[TBL] [Abstract][Full Text] [Related]
6. The role of everolimus in treatment of cardiac allograft vasculopathy.
Watanabe T
J Cardiol Cases; 2013 Jun; 7(6):e184-e185. PubMed ID: 30533159
[No Abstract] [Full Text] [Related]
7. Early Everolimus Initiation Fails to Counteract the Cytotoxic Response Mediated by CD8
Díaz-Molina B; Diaz-Bulnes P; Carvajal Palao R; Bernardo MJ; Rodriguez RM; Corte-Iglesias V; Moris de la Tassa C; Lambert JL; Suarez-Alvarez B
Front Immunol; 2018; 9():2181. PubMed ID: 30319636
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-35 mitigates the function of murine transplanted islet cells via regulation of Treg/Th17 ratio.
Zongyi Y; Funian Z; Hao L; Xin W; Ying C; Jialin Z; Yongfeng L; Baifeng L
PLoS One; 2017; 12(12):e0189617. PubMed ID: 29236782
[TBL] [Abstract][Full Text] [Related]
9. Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?
Gude E; Gullestad L; Andreassen AK
Curr Opin Organ Transplant; 2017 Jun; 22(3):198-206. PubMed ID: 28463861
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
11. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
Mirza K; Gustafsson F; Gullestad L; Arora S; Andersen C
Transpl Immunol; 2016 Sep; 38():75-7. PubMed ID: 27260644
[TBL] [Abstract][Full Text] [Related]
12. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
[TBL] [Abstract][Full Text] [Related]
13. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
[TBL] [Abstract][Full Text] [Related]
14. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
